Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

A Study of Optical Imaging With Light From Radiotracers in Cancer Patients

Active, not recruiting

Conditions: Thyroid Cancer

Interventions: Diagnostic Test: Cerenkov luminescence imaging.

First Posted Date: 2018-04-02

Last Posted Date: 2025-01-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 102

Registration Number: NCT03484884

Locations: 🇺🇸
Memorial Sloan - Kettering Cancer Center, New York, New York, United States

New MRI Biomarkers in Head and Neck Cancers

Recruiting

Conditions: Head and Neck Cancer
Thyroid Cancer

Interventions: Other: MRI examinations

First Posted Date: 2018-03-30

Last Posted Date: 2024-10-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 200

Registration Number: NCT03483337

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Developing Non-Communicable Disease Registries in Africa : A Step Towards Providing Quality Data for Improving Patient Outcomes

Conditions: Non-Communicable Disease

Interventions: Behavioral: Questionnaire forms
Other: Bio-specimen samples

First Posted Date: 2018-03-22

Last Posted Date: 2024-05-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 10000

Registration Number: NCT03473795

Locations: 🇳🇬
National Hospital of Abuja (Data collection only), Abuja, Central Business District, Nigeria
🇳🇬
Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC), Ile-Ife, Nigeria
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 9 locations

Improving Planned Surgical Case Duration Accuracy by Leveraging the EHR and Predictive Modeling

Completed

Conditions: Operative Time

Interventions: Other: standard scheduling process
Other: assigned a planned case duration value from predictive model

First Posted Date: 2018-03-20

Last Posted Date: 2022-03-17

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 683

Registration Number: NCT03471377

Locations: 🇺🇸
Memoral Sloan Kettering Basking Ridge, New York, New York, United States

Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma

Phase 2

Terminated

Conditions: Lymphoma

Interventions: Drug: atezolizumab
Radiation: Low- Dose, Local Radiotherapy

First Posted Date: 2018-03-14

Last Posted Date: 2021-01-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 2

Registration Number: NCT03465891

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 3 locations

A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors

Phase 1

Active, not recruiting

Conditions: Pituitary Adenoma
Brain Cancer

Interventions: Drug: 89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging
Other: Blood and Urine samples

First Posted Date: 2018-03-14

Last Posted Date: 2024-04-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT03465618

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Easing Psychosocial Burden for Informal Caregivers

Early Phase 1

Completed

Conditions: Glioblastoma

Interventions: Behavioral: Focus Group
Behavioral: Meaning-Centered Psychotherapy for Cancer Caregivers / MCP-C
Behavioral: Enhanced Usual Care / EUC

First Posted Date: 2018-03-05

Last Posted Date: 2024-04-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 64

Registration Number: NCT03454295

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Commack (Consent only), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester (Consent only), Harrison, New York, United States

Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas

Recruiting

Conditions: Osteosarcoma
Chondrosarcoma
Bone Sarcoma
Ewing's Sarcoma
Bone Neoplasm
Osseous Sarcoma

Interventions: Behavioral: Toronto Extremity Salvage Score
Behavioral: Musculoskeletal Tumor Society Score
Behavioral: Timed Get Up and Go Test
Diagnostic Test: Orthogonal Radiographs
Diagnostic Test: Weight Bearing for lower extremities only
Diagnostic Test: Range of Motion

First Posted Date: 2018-02-22

Last Posted Date: 2024-11-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 180

Registration Number: NCT03442465

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth (Consent and Followup), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Westchester (Consent and Followup), Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Apalutamide
Drug: Abiraterone Acetate
Radiation: Stereotactic Body Radiation Therapy
Procedure: Extended Pelvic lymphadenectomy
Drug: Prednisone
Procedure: Radical Prostatectomy
Drug: GnRH agonist/antagonist

First Posted Date: 2018-02-19

Last Posted Date: 2024-11-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 102

Registration Number: NCT03436654

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Northwestern University, Evanston, Illinois, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 8 locations

Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Myelodysplastic-Myeloproliferative Diseases
Leukemia
Acute Lymphoblastic Leukemia
Hodgkin Lymphoma
Acute Leukemia
Myelodysplastic Syndromes
Myeloproliferative Disorder
Non Hodgkin Lymphoma

Interventions: Radiation: Total Body Irradiation
Drug: Cyclosporine
Drug: Mycophenolate Mofetil
Drug: Tocilizumab
Drug: Filgrastim

First Posted Date: 2018-02-15

Last Posted Date: 2024-03-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 46

Registration Number: NCT03434730

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy